BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...out some of the worst of the pandemic’s collateral...
...sharing; keep it coming folks.Worst of the collateral...
...— BioCentury’s editorial team highlights the pandemic’s collateral...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

...some of the worst of the pandemic's collateral...
...have picked out some of the other collateral...
...see these as a sort of ripple collateral...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

...with bispecifics maybe it's a sort of collateral...
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...platforms rely on CRISPR systems with a collateral...
BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

...patent for Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB) does apply under the principles of collateral...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

...intrusive. You want them to bring expertise and advice, but not be driven by them.” Collateral...
BioCentury | Mar 28, 2020
Product Development

COVID-19 crisis spurs innovation in rapid diagnostic technologies

...once the genetic material is amplified. The CRISPR-based tests involve targeting a CRISPR enzyme with collateral...
BioCentury | Mar 13, 2020
Emerging Company Profile

Twelve Bio: Building a plug-and-play CRISPR platform with Cas12a variants

...sequence compared with the more commonly used CRISPR-Cas9 system. However, unlike Cas9, Cas12a also performs collateral...
...a Cas12a variant that recognizes but does not cleave its target strand DNA and retains collateral...
...idea is that by keeping the target DNA intact, Twelve Bio’s Cas12a variant can prolong collateral...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...patients selected for endovascular thrombectomy (EVT) who had a small, established infarct core and good collateral...
BioCentury | Feb 19, 2020
Product Development

COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

...a white paper updated on Tuesday. Results of the Cas12a-based diagnostic, which works by triggering collateral...
Items per page:
1 - 10 of 167
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...out some of the worst of the pandemic’s collateral...
...sharing; keep it coming folks.Worst of the collateral...
...— BioCentury’s editorial team highlights the pandemic’s collateral...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

...some of the worst of the pandemic's collateral...
...have picked out some of the other collateral...
...see these as a sort of ripple collateral...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

...with bispecifics maybe it's a sort of collateral...
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...platforms rely on CRISPR systems with a collateral...
BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

...patent for Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB) does apply under the principles of collateral...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

...intrusive. You want them to bring expertise and advice, but not be driven by them.” Collateral...
BioCentury | Mar 28, 2020
Product Development

COVID-19 crisis spurs innovation in rapid diagnostic technologies

...once the genetic material is amplified. The CRISPR-based tests involve targeting a CRISPR enzyme with collateral...
BioCentury | Mar 13, 2020
Emerging Company Profile

Twelve Bio: Building a plug-and-play CRISPR platform with Cas12a variants

...sequence compared with the more commonly used CRISPR-Cas9 system. However, unlike Cas9, Cas12a also performs collateral...
...a Cas12a variant that recognizes but does not cleave its target strand DNA and retains collateral...
...idea is that by keeping the target DNA intact, Twelve Bio’s Cas12a variant can prolong collateral...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...patients selected for endovascular thrombectomy (EVT) who had a small, established infarct core and good collateral...
BioCentury | Feb 19, 2020
Product Development

COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

...a white paper updated on Tuesday. Results of the Cas12a-based diagnostic, which works by triggering collateral...
Items per page:
1 - 10 of 167